Skip to main content
Erschienen in:

23.06.2017

Six-Minute Walk Test as a Predictor of Diagnosis, Disease Severity, and Clinical Outcomes in Scleroderma-Associated Pulmonary Hypertension: The DIBOSA Study

verfasst von: Abhishek Gadre, Christian Ghattas, Xiaozhen Han, Xiaofeng Wang, Omar Minai, Kristin B. Highland

Erschienen in: Lung | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Pulmonary hypertension (PH) is a common complication of scleroderma (SSc) and is a leading cause of morbidity and mortality.

Objectives

To explore the utility of the 6MWT in the prediction of SSc-PH and to assess its prognostic implications.

Methods

A retrospective review of SSc patients from 2003 to 2013, with 6MWT and echocardiogram (n = 286), was conducted. Presence of PH was defined by right heart catheterization. Patients were randomized into development and validation cohorts. Using regression techniques, we developed a scoring system to predict the presence of SSc-PH and tested it in our validation cohort. Trends of mortality and disease severity were studied for incremental scores.

Results

The DIBOSA scoring system includes DIstance walked in 6 min, BOrg dyspnea index, and SAturation of oxygen at 6 min. The DIBOSA score in the development cohort ranged from 0 to 3, resulting in an area of 0.858 (P < 0.0001) under the ROC curve. A score of 0 had a NPV of 100% and a score of 3 had a PPV of 86.58%. The validation cohort had an area under the ROC curve of 0.842. The DIBOSA score correlated with both pulmonary artery pressures and mortality. The 3-year survival rates for DIBOSA scores of 0, 1, 2, and 3 were 100, 100, 87.67, and 66.67%, respectively (HR = 3.92, P < 0.0001).

Conclusions

DIBOSA score is a sensitive tool for the prediction of SSc-PH. The DIBOSA score is a direct predictor of mortality in SSc-PH and strongly correlates with pulmonary pressures. 6MWT can be used to predict clinical outcomes in SSc-PH.
Literatur
1.
Zurück zum Zitat Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62(11):1088–1093CrossRefPubMedPubMedCentral Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62(11):1088–1093CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52(12):3792–3800CrossRefPubMed Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52(12):3792–3800CrossRefPubMed
3.
Zurück zum Zitat Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB et al (2010) Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138(6):1383–1394CrossRefPubMedPubMedCentral Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB et al (2010) Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138(6):1383–1394CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G et al (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630):2093–2100CrossRefPubMed Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G et al (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630):2093–2100CrossRefPubMed
5.
Zurück zum Zitat Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D et al (2011) Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 63(11):3522–3530CrossRefPubMed Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D et al (2011) Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 63(11):3522–3530CrossRefPubMed
6.
Zurück zum Zitat Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE et al (2013) Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 65(12):3194–3201CrossRefPubMed Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE et al (2013) Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 65(12):3194–3201CrossRefPubMed
7.
Zurück zum Zitat Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73(7):1340–1349CrossRefPubMed Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73(7):1340–1349CrossRefPubMed
8.
Zurück zum Zitat Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C et al (2015) A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 17:7CrossRefPubMedPubMedCentral Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C et al (2015) A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 17:7CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Meune C, Avouac J, Airò P, Beretta L, Dieudé P, Wahbi K et al (2011) Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 63(9):2790–2796CrossRefPubMed Meune C, Avouac J, Airò P, Beretta L, Dieudé P, Wahbi K et al (2011) Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 63(9):2790–2796CrossRefPubMed
10.
Zurück zum Zitat Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M et al (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161(2 P 1):487–492CrossRefPubMed Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M et al (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161(2 P 1):487–492CrossRefPubMed
11.
Zurück zum Zitat Garin MC, Highland KB, Silver RM, Strange C (2009) Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 36(2):330–336CrossRefPubMed Garin MC, Highland KB, Silver RM, Strange C (2009) Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 36(2):330–336CrossRefPubMed
12.
Zurück zum Zitat Impens A, Wangkaew S, Seibold J (2008) The 6-minute walk test in scleroderma—how measuring everything measures nothing. Rheumatology 47(suppl 5):v68–v69CrossRefPubMed Impens A, Wangkaew S, Seibold J (2008) The 6-minute walk test in scleroderma—how measuring everything measures nothing. Rheumatology 47(suppl 5):v68–v69CrossRefPubMed
13.
Zurück zum Zitat Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M (2001) Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 17(4):647–652CrossRefPubMed Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M (2001) Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 17(4):647–652CrossRefPubMed
14.
Zurück zum Zitat Minai OA, Nguyen Q, Mummadi S, Walker E, McCarthy K, Dweik RA (2015) Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension. Pulm Circ 5(3):565–576CrossRefPubMedPubMedCentral Minai OA, Nguyen Q, Mummadi S, Walker E, McCarthy K, Dweik RA (2015) Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension. Pulm Circ 5(3):565–576CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Laboratories ATSCoPSfCPF (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166(1):111–117CrossRef Laboratories ATSCoPSfCPF (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166(1):111–117CrossRef
16.
Zurück zum Zitat Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2015) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46(4):903–975CrossRefPubMed Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2015) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46(4):903–975CrossRefPubMed
17.
Zurück zum Zitat Phung S, Strange G, Chung LP, Leong J, Dalton B, Roddy J et al (2009) Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 39(10):682–691CrossRefPubMed Phung S, Strange G, Chung LP, Leong J, Dalton B, Roddy J et al (2009) Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 39(10):682–691CrossRefPubMed
18.
Zurück zum Zitat Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36(2):239–243CrossRefPubMed Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36(2):239–243CrossRefPubMed
19.
Zurück zum Zitat Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248–1254CrossRefPubMed Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248–1254CrossRefPubMed
22.
Zurück zum Zitat Bursac Z, Gauss CH, Williams DK, Hosmer DW (2008) Purposeful selection of variables in logistic regression. Sour Code Biol Med 3:17CrossRef Bursac Z, Gauss CH, Williams DK, Hosmer DW (2008) Purposeful selection of variables in logistic regression. Sour Code Biol Med 3:17CrossRef
23.
Zurück zum Zitat Hajian-Tilaki K (2013) Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Casp J Intern Med 4(2):627–635 Hajian-Tilaki K (2013) Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Casp J Intern Med 4(2):627–635
25.
Zurück zum Zitat Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW (2010) A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg 143(3):331–336CrossRefPubMedPubMedCentral Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW (2010) A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg 143(3):331–336CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Batal O, Khatib OF, Dweik RA, Hammel JP, McCarthy K, Minai OA (2012) Comparison of baseline predictors of prognosis in pulmonary arterial hypertension in patients surviving </=2 years and those surviving >/=5 years after baseline right-sided cardiac catheterization. Am J Cardiol 109(10):1514–1520CrossRefPubMed Batal O, Khatib OF, Dweik RA, Hammel JP, McCarthy K, Minai OA (2012) Comparison of baseline predictors of prognosis in pulmonary arterial hypertension in patients surviving </=2 years and those surviving >/=5 years after baseline right-sided cardiac catheterization. Am J Cardiol 109(10):1514–1520CrossRefPubMed
27.
Zurück zum Zitat Minai OA, Gudavalli R, Mummadi S, Liu X, McCarthy K, Dweik RA (2012) Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 185(4):400–408CrossRefPubMed Minai OA, Gudavalli R, Mummadi S, Liu X, McCarthy K, Dweik RA (2012) Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 185(4):400–408CrossRefPubMed
28.
Zurück zum Zitat Caminati A, Harari S (2010) IPF: new insight in diagnosis and prognosis. Respir Med 104(Suppl 1):S2–S10CrossRefPubMed Caminati A, Harari S (2010) IPF: new insight in diagnosis and prognosis. Respir Med 104(Suppl 1):S2–S10CrossRefPubMed
29.
Zurück zum Zitat Tugwell P, Boers M, D’Agostino MA, Beaton D, Boonen A, Bingham CO 3rd et al (2014) Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of “truth”: content, face, and construct validity. J Rheumatol 41(5):1000–1004CrossRefPubMedPubMedCentral Tugwell P, Boers M, D’Agostino MA, Beaton D, Boonen A, Bingham CO 3rd et al (2014) Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of “truth”: content, face, and construct validity. J Rheumatol 41(5):1000–1004CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Fischer A, Swigris JJ, Groshong SD, Cool CD, Sahin H, Lynch DA et al (2008) Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 134(3):601–605CrossRefPubMed Fischer A, Swigris JJ, Groshong SD, Cool CD, Sahin H, Lynch DA et al (2008) Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 134(3):601–605CrossRefPubMed
31.
Zurück zum Zitat Kane GC, Varga J, Conant EF, Spirn PW, Jimenez S, Fish JE (1996) Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir Med 90(4):223–230CrossRefPubMed Kane GC, Varga J, Conant EF, Spirn PW, Jimenez S, Fish JE (1996) Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir Med 90(4):223–230CrossRefPubMed
32.
Zurück zum Zitat Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 66(6):754–763CrossRefPubMedPubMedCentral Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 66(6):754–763CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Follansbee WP, Zerbe TR, Medsger TA Jr (1993) Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 125(1):194–203CrossRefPubMed Follansbee WP, Zerbe TR, Medsger TA Jr (1993) Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 125(1):194–203CrossRefPubMed
Metadaten
Titel
Six-Minute Walk Test as a Predictor of Diagnosis, Disease Severity, and Clinical Outcomes in Scleroderma-Associated Pulmonary Hypertension: The DIBOSA Study
verfasst von
Abhishek Gadre
Christian Ghattas
Xiaozhen Han
Xiaofeng Wang
Omar Minai
Kristin B. Highland
Publikationsdatum
23.06.2017
Verlag
Springer US
Erschienen in
Lung / Ausgabe 5/2017
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-017-0034-1

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Vorhofflimmern: Antikoagulation vor Schlaganfall von Vorteil

Erleiden Menschen mit Vorhofflimmern einen ischämischen Schlaganfall, ist dieser weniger schwer, auch sind Infarktgröße und Blutungsrisiko geringer, wenn sie zuvor orale Antikoagulanzien erhalten haben. Die Art der Antikoagulation spielt dabei keine Rolle.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Mehr Cholesterin im Essen = höheres Herzinfarktrisiko

Je mehr Cholesterin man täglich über die Nahrung zu sich nimmt, desto höher ist offenbar das Herzinfarktrisiko – das legt eine Studie mit US-Veteranen zumindest für Männer nahe.

Antikoagulation bei Vorhofflimmern: Sind DOAK noch zu toppen?

Gegen Thromboembolien so wirksam wie ein DOAK, bei zugleich geringerem Blutungsrisiko – werden Faktor-XI-Hemmer als neue Antikoagulanzien dieser Erwartung gerecht? Eine aktuell publizierte Vergleichsstudie gibt darüber Aufschluss.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.